Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific...
Reexamination Certificate
2011-04-19
2011-04-19
Canella, Karen A (Department: 1643)
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
C424S001110, C424S001570, C424S573000
Reexamination Certificate
active
07927612
ABSTRACT:
Methods for treating neoplasms, tumors and cancers, using one or more haptens and coagulation agents or treatments, alone or in combination with other anti-neoplastic agents or treatments, are provided. Also provided are combinations, and kits containing the combinations for effecting the therapy.
REFERENCES:
patent: 4160817 (1979-07-01), Bucovaz et al.
patent: 4447526 (1984-05-01), Rupchock et al.
patent: 4724230 (1988-02-01), Cone, Jr.
patent: 4832849 (1989-05-01), Cardin
patent: 4971991 (1990-11-01), Umemura et al.
patent: 5005588 (1991-04-01), Rubin
patent: 5156841 (1992-10-01), Rapp
patent: 5215899 (1993-06-01), Dattagupta
patent: 5290551 (1994-03-01), Berd
patent: 5340803 (1994-08-01), Rubin
patent: 5651986 (1997-07-01), Brem et al.
patent: 5705151 (1998-01-01), Dow et al.
patent: 5846565 (1998-12-01), Brem et al.
patent: 6248585 (2001-06-01), Berd
patent: 7041302 (2006-05-01), Roussel
patent: 240191 (1987-10-01), None
patent: 378888 (1990-07-01), None
patent: 2505182 (1982-11-01), None
patent: 11-171788 (1999-06-01), None
patent: WO96/39226 (1996-12-01), None
patent: WO 97/11666 (1997-04-01), None
patent: WO 98/03195 (1998-01-01), None
patent: WO 98/40105 (1998-09-01), None
patent: WO 99/46385 (1999-09-01), None
patent: WO 00/06143 (2000-02-01), None
Abstract of Schneider et al, Gene Ther, 1999, vol. 6, suppl. 1, S5).
Drug Facts and Comparisons, T. Burnham, Ed., 2000, p. 1807.
Martin et al, Archives of Biochemistry and Biophysics, 1987, vol. 255, pp. 329-336.
Clark (Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, 1993, pp. 4-5).
Abstract of Uehara, Can to kagaku ryoho, 1997, vol. 24, pp. 136-144.
Dasgupta et al, Experimental Cell Research, 1997, vol. 237, pp. 29-37.
Gong et al (Journal of biological Chemistry, 2000, vol. 275, pp. 3355-3359).
Barbie et al (Trends in Cell biology, 2005, vol. 15, pp. 378-385).
Jones et al., Advanced Drug Delivery Reviews 1998, p. 160,section 3).
Verma et al (Nature, 1997, vol. 389, pp. 239-242).
Orkin ( “Report and Recommendation of the Panel to Assess the NIH Investment in Research on Gene Therapy”, NIH, 1995).
Tolcher et al (Clinical Cancer Research, 2002, vol. 8, pp. 2530-2535).
Cripps et al (Clinical Cancer Research. 2002, 8, pp. 2188-2192).
Marshall et al (Clinical Colorectal Cancer, 2004, vol. 4, pp. 268-274).
Oza et al (Gynecological Oncology, 2003, vol. 89, pp. 129-133).
Paul, Fundamental Immunology, (text), 1993, pp. 1157-1170).
Abstract, Ferguson et al, Int Review Immunol, 2002, vol. 21, pp. 153-172, lines 9-12).
Cotton and Wilkinson (Advanced Inorganic Chemistry (text), 1972, p. 408).
E. Vadas, ‘Stability of Pharmaceutical Products’ in: Remmington: The Science and Practise of Pharmacy, 19th Ed., 1995, pp. 639-647.
1999 Edition of the Sigma Catalog, p. 2399.
Abstract of Coxon et al (Ann Clin Biochem, Jan. 1988, 25(pt 1), pp. 49-52).
Abstract of Mansouri (BBRC, 1979, vol. 89(2), pp. 441-447).
NLM Mesh Term information for Cytarabine, downloaded May 26, 2008.
Remington: The Science and Practice of Pharmacy, 1995, pp. 1529-1530.
Orkin et al., “Report and Recommendation of the Panel to Assess the NIH Investment in Research on Gene Therapy,” NIH, 1995.
Reiger et al., eds., Glossary of Genetics, Classical and Molecular, 5thed., (1991) p. 422.
Ferguson et al., Int. Review Immunol. (2002) 21:153-172.
Paul, Fundamental Immunology (1993) pp. 705-706, 930, 990-992.
Schneider et al., Gene Ther. (1999) 6(1):S5.
Verma et al., Nature (1997) 389:239-242.
Eck et al., Gene-Based Therapy, in The Pharmacological Basis of Therapeutics, Goodman and Gilman, (eds.), (1996) pp. 77-10.
Lisowski et al., J. Immunological Methods (1972) 1:341-352.
Todryk et al., J. Immunology (1999) 163:1398-1408.
Lin et al., J. Gastroenterology and Hepatology (1997) 12:S319-S328.
Molloy et al., J. Experimental Medicine (1994) 180:1499-1509.
Brien et al., Lasers in Surgery and Medicine (1992) 12:313-317.
Martin et al., Archives in Biochemistry and Biophysics (1987) 255:329-336.
Dima et al., Laser Therapy (1990) 2:153-160.
Krosl et al., Cancer Research (1996) 56:3281-3286.
Skobelkin et al., Laser Therapy (1991) 3:169-175.
Pan et al., Cancer Research (1989) 49:5048-5053.
Adams. Poult. Sci. 49(1):229-33 (1970).
Auerbach. Pharmacol. Ther. 63(3):265-311 (1994).
August. Clin. Dermatol. 13(6):589-92 (1995).
Aw. “Molecular and Cellular Responses to Oxidative Stress and Changes in Oxidation-Reduction Imbalance in the Intestine” (Abstract) at <http://www.ajcn.org> (visited on Jun. 6, 2002).
Awwad et al. Cancer Immunol. Immunother. 38:23-30 (1994).
Berd, et al. Cancer Research 46:2572-2577 (1986).
Berd et al. Cancer Research 51:2731-2734 (1991).
Berd et al. Journal of Clinical Oncology 15(6):2359-2370 (1997).
Berd et al. Seminars in Oncology 25(6):646-653 (1998).
Berd. Seminars in Oncology 25(6):605-610 (1998).
Bier et al. “Intratumor Immunotherapy with BCG Cell Wall Preparations: Development of a New Therapy Approach for Head-Neck Tumors” (abstract) at <http://www.ncbi.nim.nih.gov> (visited on Nov. 24, 1999).
Bingya et al. Chin. J. Oncol. 20(1):34-36 (1998).
Biochemistry 11(9):1726 (1972).
Bromberg et al. The Cancer Journal from Scientific American pp. 132-138 (1999).
Brunschwig et al. J. Immunother. 22(5):390-400 (1999).
Chakraborty et al. Cancer Immunol. Immunother. 47:58-64 (1998).
Calsini et al. “Immunotherapy of Bladder Cancer with Intralesional Injection with BCG” (Abstract) at <http://www.ncbi.nlm.nih.gov> (visited on Nov. 24, 1999).
Chamberlain. Drugs 57)3):309-325 (1999).
Chang et al. Int. J. Radiat. Oncol. Biol. Phys. 40(1):65-70 (1998).
Chang et al. Br. J. Plast. Surg. 52(3):178-81 (1999).
Chassoux et al. “Therapeutic Effect of Intratumoral Injection of bcg and Other Substances in Rats and Mice” (Abstract) at <http://www.ncbi.nim.nih.gov> (visited on Nov. 24, 1999).
Chen et al. Journal of Biomedical Science 5:231-252 (1998).
Chen et al. The Cancer Journal from Scientific American pp. 16-17 (1999).
Claman. Journal of Immunology I16(3):704-9 (1976).
Dieli et al. Int. Immunol. 9(1):1-8 (1997).
Duda et al. Annals of Surgical Oncology 2(6):542-9 (Abstract) (1995).
Fisher at al. “Comparative Effects ofCorynebacterium parvum, Brucella abortusExtract, Bacillus Calmette-Guerin, Glucan, Levamisole, and Tilorone With or Without Cyclophosphamide on Tumor Growth, Macrophage Production, and Macrophage Cytotoxicity in a Murine Mammary Tumor Model” (Abstract) at <http://www.ncbi.nlm.nih.gov> (visited on Nov. 24, 1999).
Fujiwara et al. Journal of Immunology 132(3):1571-1577 (1984).
Gavrilenko et al. Vopr. Onkol. 29(4):67-70 (1983).
Gilboa. Cancer Immunol. Immunother. 48:382-385 (1999).
Goldberg et al. Radiology 209(2):371-9 (1998).
Goldberg et al. Radiology 209(3):761-7 (1998).
Goldberg et al. Radiology 213(2):438-44 (1998).
Haas et al. “An Effective Strategy Human Tumor Vaccine Modification by Coupling Bispecific Costimulatory Molecules” (Abstract) at <http://www.cdlib.org> (visited on Nov. 28, 1999).
Haba et al. Int. J. Cancer 18(1):93-104 (1976).
Hageboutros et al. Investigational New Drugs 15:139-145 (1997).
Hawkins. Current Opinion in Oncology 7:90-93 (1995).
Helting et al. Acta Pathol. Microbiol. Immunol. Scand. 92(1):59-63 (1984).
Henderson. “Regression of Lung Metastases After Immunotherapy with Autologous, DNP-Modified Melanoma Vaccine” (Abstract) at <http://www.cdlib.org> (visited on Sep. 7, 1999).
Henderson et al. “Advances in Conventional Treatment of Breast Cancer: The Addition of BCG and Autotumour Vaccine Immunotherapy” (Abstract) at <http://www.cdlib.org> (visited on Sep. 7, 1999).
Henderson. “Cancer Immunotherapy Autologous Melanoma Cell Vaccine Generates Immunity” (Abstract) at <http://www.cdlib.org> (visited on Sep. 7, 1999).
Hess Eur. J. Immunol. 6(3):188-93 (1976).
Holmes et al. “Intralesional BCG Immunotherapy of Pulmonary Tumors” (Abstract) at <htt
Canella Karen A
Knobbe Martens Olson & Bear LLP
Yu Baofa
LandOfFree
Combinations and methods for treating neoplasms does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combinations and methods for treating neoplasms, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations and methods for treating neoplasms will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2629371